ivabradina bluepharma 7,5 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - ivabradina hidrocloruro - comprimido recubierto con pelÍcula - 7,5 mg - ivabradina hidrocloruro 7,5 mg - ivabradina
moxifloxacino bluepharma 400 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - moxifloxacino hidrocloruro - comprimido recubierto con pelÍcula - 400 mg - moxifloxacino hidrocloruro 400 mg - moxifloxacino
acido alendronico/colecalciferol semanal bluepharma 70 mg/2800 ui comprimidos efg
bluepharma industria farmaceutica s.a. - alendronico acido; colecalciferol - comprimido - 70 mg/2.800 ui - alendronico acido 70 mg; colecalciferol 2800 ui - Ácido alendrónico y colecalciferol
paroxetina bluepharma 20 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - paroxetina hidrocloruro - comprimido recubierto con pelÍcula - 20 mg - paroxetina hidrocloruro 20 mg - paroxetina
febuxostat bluepharma 120 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - febuxostat - comprimido recubierto con pelÍcula - 120 mg - febuxostat 120 mg - febuxostat
febuxostat bluepharma 80 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - febuxostat - comprimido recubierto con pelÍcula - 80 mg - febuxostat 80 mg - febuxostat
ms-h vaccine
pharmsure veterinary products europe ltd - mycoplasma synoviae strain ms-h - immunologicals para aves, viven de vacunas bacterianas - pollo - para la inmunización activa de futuro criador de pollos de engorde de pollos, el futuro de la capa de criador de pollos y futuro de la capa de pollos para reducir el aire sac lesiones y reducir el número de huevos con alteración en la formación de la cáscara del causada por mycoplasma synoviae.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
valsartan/hidroclorotiazida bluepharma 160 mg/25 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica, s.a - valsartan, hidroclorotiazida - excipientes: lactosa anhidra,lactosa monohidrato - antagonistas de angiotensina ii, combinaciones - antagonistas de angiotensina ii y diuréticos - valsartán y diuréticos
lansoprazol bluepharma 30 mg capsulas duras gastrorresistentes efg
laboratorios bluepharma s.l. - lansoprazol - cÁpsula dura gastrorresistente - 30 mg - lansoprazol 30 mg - lansoprazol